Source: CURATED ×
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0011853
Disease: Diabetes Mellitus, Experimental
Diabetes Mellitus, Experimental 		0.500 Biomarker disease CTD_human Resveratrol prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK-SIRT1-PGC1α axis in db/db mice. 23090186 2013
CUI: C0021655
Disease: Insulin Resistance
Insulin Resistance 		0.500 Biomarker phenotype CTD_human Impact of dietary fat quantity and quality on skeletal muscle fatty acid metabolism in subjects with the metabolic syndrome. 22658938 2012
CUI: C0011853
Disease: Diabetes Mellitus, Experimental
Diabetes Mellitus, Experimental 		0.500 Biomarker disease CTD_human Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets. 10900012 2000
CUI: C0015695
Disease: Fatty Liver
Fatty Liver 		0.400 Biomarker disease CTD_human A simple transcriptomic signature able to predict drug-induced hepatic steatosis. 24469900 2014
CUI: C2711227
Disease: Steatohepatitis
Steatohepatitis 		0.400 Biomarker disease CTD_human A simple transcriptomic signature able to predict drug-induced hepatic steatosis. 24469900 2014
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.400 Biomarker disease CTD_human Suppression of the genes adenosine triphosphate citrate lyase, acetyl-CoA carboxylase, fatty acid synthase, stearoyl-CoA desaturase 1, or sterol regulatory element-binding protein 1, which are involved in lipogenesis, reduced proliferation, and survival of HCC cell lines and AKT-dependent cell proliferation. 21147110 2011
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.400 Biomarker disease CTD_human Dietary alpha-linolenic acid reduces COX-2 expression and induces apoptosis of hepatoma cells. 14563831 2004
CUI: C0400966
Disease: Non-alcoholic Fatty Liver Disease
Non-alcoholic Fatty Liver Disease 		0.380 Biomarker disease CTD_human Non-alcoholic fatty liver disease is associated with inhibited AMP-activated kinase (AMPK) and activation of sterol regulatory element binding protein 1 (SREBP-1). 24633463 2014
CUI: C0400966
Disease: Non-alcoholic Fatty Liver Disease
Non-alcoholic Fatty Liver Disease 		0.380 Biomarker disease CTD_human Amelioration by chicory seed extract of diabetes- and oleic acid-induced non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) via modulation of PPARα and SREBP-1. 23603006 2013
CUI: C0028754
Disease: Obesity
Obesity 		0.370 Biomarker disease CTD_human SREBP-1 overexpression, which is prevented by troglitazone, may play a role in the ectopic lipogenesis and lipotoxicity complicating obesity in Zucker diabetic fatty rats. 10900012 2000
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.360 Biomarker disease PSYGENET We therefore conducted a HapMap-based association study in a large German sample, and identified association between schizophrenia and five markers in SREBF1 and five markers in SREBF2. 18936756 2010
CUI: C3241937
Disease: Nonalcoholic Steatohepatitis
Nonalcoholic Steatohepatitis 		0.310 Biomarker disease CTD_human Protective effect of resveratrol derivatives on high-fat diet induced fatty liver by activating AMP-activated protein kinase. 24633463 2014
CUI: C3241937
Disease: Nonalcoholic Steatohepatitis
Nonalcoholic Steatohepatitis 		0.310 Biomarker disease CTD_human Amelioration by chicory seed extract of diabetes- and oleic acid-induced non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) via modulation of PPARα and SREBP-1. 23603006 2013
CUI: C0023893
Disease: Liver Cirrhosis, Experimental
Liver Cirrhosis, Experimental 		0.300 Biomarker disease CTD_human Systems level analysis and identification of pathways and networks associated with liver fibrosis. 25380136 2014
CUI: C0002152
Disease: Alloxan Diabetes
Alloxan Diabetes 		0.300 Biomarker disease CTD_human Resveratrol prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK-SIRT1-PGC1α axis in db/db mice. 23090186 2013
CUI: C0038433
Disease: Streptozotocin Diabetes
Streptozotocin Diabetes 		0.300 Biomarker disease CTD_human Resveratrol prevents renal lipotoxicity and inhibits mesangial cell glucotoxicity in a manner dependent on the AMPK-SIRT1-PGC1α axis in db/db mice. 23090186 2013
CUI: C0920563
Disease: Insulin Sensitivity
Insulin Sensitivity 		0.300 Biomarker phenotype CTD_human Impact of dietary fat quantity and quality on skeletal muscle fatty acid metabolism in subjects with the metabolic syndrome. 22658938 2012
CUI: C0022661
Disease: Kidney Failure, Chronic
Kidney Failure, Chronic 		0.300 Biomarker disease CTD_human CRF resulted in hypertension, proteinuria, renal tissue lipid accumulation, up-regulation of scavenger receptor A1 (SR-A1), acyl-CoA cholesterol acyltransferase-1 (ACAT1), carbohydrate-responsive element binding protein (ChREBP), fatty acid synthase (FAS), acyl-CoA carboxylase (ACC), liver X receptor (LXR), ATP binding cassette (ABC) A-1, ABCG-1, and SR-B1 and down-regulation of sterol responsive element binding protein-1 (SREBP-1), SREBP-2, HMG-CoA reductase, PPAR-alpha, fatty acid binding protein (L-FABP), and CPT1A. 19878707 2010
CUI: C0002152
Disease: Alloxan Diabetes
Alloxan Diabetes 		0.300 Biomarker disease CTD_human Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets. 10900012 2000
CUI: C0038433
Disease: Streptozotocin Diabetes
Streptozotocin Diabetes 		0.300 Biomarker disease CTD_human Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets. 10900012 2000